These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18683085)

  • 1. American Diabetes Association--68th Scientific Sessions. Results for ACCORD, ADVANCE and other clinical trials.
    Glah D
    IDrugs; 2008 Aug; 11(8):550-2. PubMed ID: 18683085
    [No Abstract]   [Full Text] [Related]  

  • 2. American Diabetes Association--68th Scientific Sessions. Clinical trial results.
    Glah D
    IDrugs; 2008 Aug; 11(8):556-8. PubMed ID: 18683087
    [No Abstract]   [Full Text] [Related]  

  • 3. Options for intensifying diabetes treatment.
    Reid TS
    J Fam Pract; 2011 Sep; 60(9 Suppl):S7-10. PubMed ID: 21912777
    [No Abstract]   [Full Text] [Related]  

  • 4. [New therapeutic approaches in type 2 diabetes mellitus].
    Zafon C
    Med Clin (Barc); 2015 Dec; 145(11):485-7. PubMed ID: 26142571
    [No Abstract]   [Full Text] [Related]  

  • 5. Higher type 2 diabetes-related mortality when HbA1c levels are too low.
    Prescrire Int; 2008 Oct; 17(97):213. PubMed ID: 19536943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians.
    Dhar GC
    Can Fam Physician; 2009 Aug; 55(8):803-4. PubMed ID: 19675265
    [No Abstract]   [Full Text] [Related]  

  • 7. [Glycemic control and diabetic complications].
    Yamada Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():604-8. PubMed ID: 15999778
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes specialists keep ACCORD data in perspective.
    Traynor K
    Am J Health Syst Pharm; 2008 Mar; 65(6):488, 490. PubMed ID: 18319488
    [No Abstract]   [Full Text] [Related]  

  • 9. Type 2 diabetes: target HbA1c of about 7%.
    Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glimepiride--well tolerated in daily practice.
    Cardiovasc J S Afr; 2002; 13(4):214-5. PubMed ID: 12402929
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient-important outcomes in diabetes--time for consensus.
    Montori VM; Gandhi GY; Guyatt GH
    Lancet; 2007 Sep; 370(9593):1104-6. PubMed ID: 17905147
    [No Abstract]   [Full Text] [Related]  

  • 12. [What is really an optimal treatment in type 2 diabetes? New studies call for reflection].
    Nilsson PM; Eliasson B
    Lakartidningen; 2008 Apr 2-8; 105(14):985-6. PubMed ID: 18478745
    [No Abstract]   [Full Text] [Related]  

  • 13. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
    Terry T; Raravikar K; Chokrungvaranon N; Reaven PD
    Curr Cardiol Rep; 2012 Feb; 14(1):79-88. PubMed ID: 22160862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of type 2 diabetes with incretin-based therapies.
    Madsbad S
    Lancet; 2009 Feb; 373(9662):438-9. PubMed ID: 18819704
    [No Abstract]   [Full Text] [Related]  

  • 15. Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes.
    Kanzer-Lewis G
    Diabetes Educ; 2003; 29(6):954-8, 961. PubMed ID: 14692369
    [No Abstract]   [Full Text] [Related]  

  • 16. [SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications].
    Kojima N; Samukawa Y; Takahashi T
    Nihon Yakurigaku Zasshi; 2016; 148(5):253-258. PubMed ID: 27803438
    [No Abstract]   [Full Text] [Related]  

  • 17. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
    Elkeles RS
    Diabet Med; 2014 Jul; 31(7):880. PubMed ID: 24588426
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical inquiries. How beneficial are thiazolidinediones for diabetes mellitus?
    Culhane NS; Graves R
    J Fam Pract; 2002 May; 51(5):424. PubMed ID: 12019048
    [No Abstract]   [Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease.
    Smilowitz NR; Donnino R; Schwartzbard A
    Circulation; 2014 Jun; 129(22):2305-12. PubMed ID: 24891623
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of complications in type 2 diabetes: is drug glucose control evidence based?
    Boussageon R; Pouchain D; Renard V
    Br J Gen Pract; 2017 Feb; 67(655):85-87. PubMed ID: 28126879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.